The metabolic effects of preferential reduction of visceral adipose tissue in abdominally obese men

International Journal of Obesity

Volumn 22, Issue 9, 1998, Pages 893-898

  Marks, S J ^a   Chin, S ^a   Strauss, B J G ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

Body composition; Dexfenfluramine; Metabolic syndrome; MRI; Obesity; Visceral fat; Weight loss

Indexed keywords

CHOLESTEROL; DEXFENFLURAMINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMEN; ARTICLE; BLOOD PRESSURE; BODY BUILD; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031829978     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0800678     Document Type: Article

References (14)

1. Bremen JM, Scott RS, Lintott CJ. Dexfenfluramine reduces cardiovascular risk factors. Int J Obes 1994; 18: 199-205.
2. Swinburn BA, Carmichael HE, Wilson MR. Dexfenfluramine as an adjunct to a reduced fat ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. Int J Obes 1996; 20: 1033-1040.
3. Holiway IM, Wallace E, Westbrooke L, Gamble G. Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol 1 obese individuals. Int J Obes 1995; 19: 749-751.
4. Marks SJ, Moore NR, Clark ML, Strauss BJ, Hockaday TD. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res 1996; 4: 1-7.
5. Kanal H, Tokunaya K, Fujioka S, Yainashuta S, Kameda-Takemura KK, Matsuzawa Y. Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 1996; 27: 125-129.
6. Tochikubo O, Miyajima E, Okabe K, Imai K, Ishii M. Improvement of multiple coronary risk factors in obese hypertensives by reduction of intra-abdominal visceral fat. Jpn Heart J 1994; 35: 715-725.
7. Buemann B, Tremblay A. Effects of exercise training on abdominal obesity and related metabolic complications. Sports Med 1996; 21: 191-212.
8. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration for low-density lipoprotein cholesterol in plasma without the use of the preparative ultra-centrifuge. Clin Chem 1972; 18: 499-502.
9. Gray DS, Fujioka K, Colletti PM, Kim H, Devine W, Cuyegkeng T, Pappas T. Magnetic-resonance imaging used for determining fat distribution in obesity and diabetes. Am J Clin Nutr 1991; 54: 623-627.
10. Fujioka S, Matsuzawa Y, Tokunaga K, Kawainoto T, Kobatake T, Keno Y, Kotani K, Yoshida S, Tarui S. Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in pre-menopausal women with visceral fat obesity. Int J Obes 1991; 15: 853-885.
11. Ross R, Rissanen J. Mobilization of visceral and subcutaneous adipose tissue in response to energy restriction and exercise. Am J Clin Nutr 1994; 60: 695-703.
12. Visser M, Seidell J, Koppeschaar HPF, Smits P. The effects of fluoxetine on body weight, body composition and visceral fat accumulation. Int J Obes 1993; 17: 247-253.
13. Van der Merwe MT, Wing JR, Celgow LH, Gray IP, Lonn L, Joffe BI, Lannroth PN. Metabolic indices in relation to body composition changes during weight loss on dexfenfluramine in obese women from two South African ethnic groups. Int J Obes 1996; 20: 768-776.
14. Pfohl M, Luft D, Blomberg I, Schmulling RM. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. Int J Obes 1994; 18: 391-395.